Toremifene, sold under the brand name Fareston among others, is a medication which is used in the treatment of advanced breast cancer in postmenopausal women.   It is taken  by mouth.
 Side effects of toremifene include hot flashes, sweating, nausea, vomiting, dizziness, vaginal discharge, and vaginal bleeding.  It can also cause  blood clots, irregular heartbeat, cataracts, visual disturbances, elevated liver enzymes, endometrial hyperplasia, and endometrial cancer.  High blood calcium levels can occur in women with bone metastases.
The drug is a
selective estrogen receptor modulator (SERM) and hence is a mixed agonist– antagonist of the estrogen receptor (ER), the biological target of estrogens like estradiol.  It has  estrogenic effects in bone, the liver, and the uterus and antiestrogenic effects in the breasts.    It is a  triphenylethylene derivative and is closely related to tamoxifen.
Toremifene was introduced for medical use in 1997.
 It was the first  antiestrogen to be introduced since tamoxifen in 1978. It is not available as a  generic medication in the United States.
Toremifene is approved for the treatment of
metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown-status tumors.  This is its only approved use in the  United States. It shows equivalent effectiveness to tamoxifen for this indication.  Toremifene has been found to be effective in the treatment of  breast pain and may be a better drug than tamoxifen for this indication. Toremifene has been reported to significantly improve symptoms of  gynecomastia in men.
side effects of toremifene are similar to those of tamoxifen. The most common side effect is  hot flashes. Other side effects include  sweating, nausea, vomiting, dizziness, vaginal discharge, and vaginal bleeding.  In women with  bone metastases, hypercalcemia may occur. Toremifene has a small risk of  thromboembolic events.  Cataracts, vision changes, and elevation of liver enzymes have been reported.  The drug  prolongs the QT interval and hence has a risk of potentially fatal dysrhythmias. The risk of dysrhythmias can be reduced by avoiding use in patients with  hypokalemia, hypomagnesemia, pre-existing QT prolongation, and in those taking other QT-prolonging drugs. Because toremifene has  estrogenic actions in the uterus, it can increase the risk of endometrial hyperplasia and endometrial cancer.
Toremifene is a
substrate of CYP3A4, a cytochrome P450 enzyme, and hence drugs that induce or inhibit this enzyme can respectively decrease or increase levels of toremifene in the body.
Toremifene is a
competitive ligand of the estrogen receptor and has mixed agonistic and antagonistic actions in a tissue-selective manner.  It has  estrogenic activity in bone, partial estrogenic activity in the uterus and liver, and pure antiestrogenic activity in the breasts.    The drug is very similar to  tamoxifen and shares most of its properties.    There are some indications that it may be safer than tamoxifen as it is not a  hepatocarcinogen in animals and may have less potential for genotoxicity.  However, clinical studies have found no significant differences between toremifene and tamoxifen, including in terms of  effectiveness, tolerability, and safety, and hence the clinical use of toremifene has been somewhat limited. 
Toremifene has been found to have
antigonadotropic effects in postmenopausal women,  progonadotropic effects in men, to increase  sex hormone-binding globulin levels, and to decrease  insulin-like growth factor 1 levels by about 20% in postmenopausal women and men.
Toremifene has about one-third of the
potency of tamoxifen; i.e., 60 mg toremifene is roughly equivalent to 20 mg tamoxifen in the treatment of breast cancer.
bioavailability of toremifene has not been precisely determined but is known to be good. The drug is more than 99%  bound to plasma proteins. It is  metabolized in the liver primarily by CYP3A4 and then undergoes secondary hydroxylation. The  metabolites of toremifene include N-desmethyltoremifene and 4-hydroxytoremifene and are less active than toremifene itself.   Ospemifene (deaminohydroxytoremifene) is also a major metabolite of toremifene. Toremifene and 4-hydroxytoremifene have a very long  elimination half-life of 5 to 6 days, while N-desmethyltoremifene has an even longer elimination half-life of 6 to 21 days and ospemifene has an elimination half-life of 4 days.  The long elimination half-lives of toremifene and its metabolites can be attributed to  enterohepatic recirculation. Toremifene is  eliminated 70% in the feces, as metabolites.
Unlike tamoxifen, toremifene is not a
prodrug and does not depend on metabolism by CYP2D6 for bioactivation; hence, it may be preferable to tamoxifen in CYP2D6 poor metabolizers or in patients who are taking a drug that inhibits CYP2D6.
Toremifene, also known as
4-chlorotamoxifen, is a derivative of triphenylethylene and a close analogue of tamoxifen. It is also closely related to  afimoxifene (4-hydroxytamoxifen) and ospemifene (deaminohydroxytoremifene). 
Toremifene was introduced in the
United States in 1997.  It was the first  antiestrogen to be introduced in this country since tamoxifen in 1978.
Society and culture
Toremifene is the generic name of the drug and its and INN , while BAN toremifene citrate is its and USAN and JAN torémifène is its . DCF   
Toremifene is marketed almost exclusively under the brand name Fareston.
Toremifene is marketed widely throughout the world and is available in the
United States, the United Kingdom, Ireland, many other European countries, South Africa, Australia, New Zealand, and elsewhere throughout the world. 
Toremifene was also evaluated for prevention of
prostate cancer and had the tentative brand name Acapodene.
In 2007 the pharmaceutical company
GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008
An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009,
and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial. 
Ultimately, development was discontinued and toremifene was never marketed for complications associated with ADT or the treatment or prevention of prostate cancer.
^ a b c d e f g h i j k l m n o p q r s t
Laura Rosenthal; Jacqueline Burchum (17 February 2017). . Elsevier Health Sciences. pp. 931–. Lehne's Pharmacotherapeutics for Advanced Practice Providers - E-Book ISBN 978-0-323-44779-9.
^ a b c d e f g h i j k l
Vincent T. DeVita Jr.; Theodore S. Lawrence; Steven A. Rosenberg (7 January 2015). . Wolters Kluwer Health. pp. 1126–. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology ISBN 978-1-4698-9455-3.
^ a b c d e
Bruce A. Chabner; Dan L. Longo (7 December 2011). . Lippincott Williams & Wilkins. pp. 659–. Cancer Chemotherapy and Biotherapy: Principles and Practice ISBN 978-1-4511-4820-6.
^ a b c d e
^ a b c
^ a b c d e f g h
William R. Miller; James N. Ingle (8 March 2002). . CRC Press. pp. 55–57. Endocrine Therapy in Breast Cancer ISBN 978-0-203-90983-6.
^ a b c d e
David Schiff; Isabel Arrillaga; Patrick Y. Wen (16 September 2017). . Humana Press. pp. 296–. Cancer Neurology in Clinical Practice: Neurological Complications of Cancer and its Treatment ISBN 978-3-319-57901-6.
^ a b c
Monica Morrow; Virgil Craig Jordan (2003). . PMPH-USA. pp. 192–. Managing Breast Cancer Risk ISBN 978-1-55009-260-8.
^ a b c
. ScholarlyEditions. 1 May 2013. pp. 51–. Selective Estrogen Receptor Modulators—Advances in Research and Application: 2013 Edition: ScholarlyBrief ISBN 978-1-4901-0447-8.
^ a b
Antonio Cano; Joacquim Calaf i Alsina; Jose Luis Duenas-Diez (22 September 2006). . Springer Science & Business Media. pp. 52–. Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs ISBN 978-3-540-34742-2.
^ a b
Orlando E. Silva; Stefano Zurrida (2005). . Elsevier Health Sciences. pp. 355–. Breast Cancer: A Practical Guide ISBN 0-7020-2744-8.
^ a b
Wayne R. Bidlack; Stanley T. Omaye; Mark S. Meskin; Debra K.W. Topham (16 March 2000). . CRC Press. pp. 26–. Phytochemicals as Bioactive Agents ISBN 978-1-56676-788-0.
^ a b
Philip J. DiSaia; William T. Creasman; Robert S Mannel; D. Scott McMeekin, David G Mutch (4 February 2017). . Elsevier Health Sciences. pp. 124–. Clinical Gynecologic Oncology E-Book ISBN 978-0-323-44316-6.
"Generic Fareston Availability - Drugs.com". Drugs.com . Retrieved . 2018-02-08
Kirby I. Bland; Edward M. Copeland; V. Suzanne Klimberg; William J Gradishar (29 June 2017). . Elsevier Health Sciences. pp. 86–. The Breast E-Book: Comprehensive Management of Benign and Malignant Diseases ISBN 978-0-323-51187-2.
Tabbal, Mahmoud; Fuleihan, Ghada El-Hajj (2010). "Future Therapies": 713–732. doi: 10.1016/B978-0-12-374602-3.00057-2.
^ a b
Ellmén J, Hakulinen P, Partanen A, Hayes DF (November 2003). "Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients". Breast Cancer Res. Treat. 82 (2): 103–11. doi: 10.1023/B:BREA.0000003957.54851.11. PMID 14692654.
Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D (April 2009). "The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia". Fertil. Steril. 91 (4 Suppl): 1427–30. doi: 10.1016/j.fertnstert.2008.06.002. PMID 18692782.
Roelfsema F, Yang RJ, Takahashi PY, Erickson D, Bowers CY, Veldhuis JD (February 2018). "Effects of Toremifene, a Selective Estrogen Receptor Modulator, on Spontaneous and Stimulated GH Secretion, IGF-I, and IGF-Binding Proteins in Healthy Elderly Subjects". J Endocr Soc. 2 (2): 154–165. doi: 10.1210/js.2017-00457. PMC . 5789038 PMID 29383334.
MacGregor JI, Jordan VC (June 1998). "Basic guide to the mechanisms of antiestrogen action". Pharmacol. Rev. 50 (2): 151–96. PMID 9647865.
George M. Brenner; Craig Stevens (28 September 2017). . Elsevier Health Sciences. pp. 394–. Brenner and Stevens’ Pharmacology E-Book ISBN 978-0-323-39172-6.
^ a b
Georg F. Weber (22 July 2015). . Springer. pp. 304–. Molecular Therapies of Cancer ISBN 978-3-319-13278-5.
Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). . Springer Science & Business Media. pp. 170–. Tamoxifen: Pioneering Medicine in Breast Cancer ISBN 978-3-0348-0664-0.
J. Elks (14 November 2014). . Springer. pp. 1222–. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies ISBN 978-1-4757-2085-3.
^ a b c
. Taylor & Francis. 2000. pp. 1048–. Index Nominum 2000: International Drug Directory ISBN 978-3-88763-075-1.
I.K. Morton; Judith M. Hall (6 December 2012). . Springer Science & Business Media. pp. 277–. Concise Dictionary of Pharmacological Agents: Properties and Synonyms ISBN 978-94-011-4439-1.
^ a b c
"Toremifene - Drugs.com". Drugs.com . Retrieved . 2018-02-08
^ Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer.
Clin Prostate Cancer 2005;3:211-4. PMID 15882476
"GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review" (Press release). GTx Inc. 2007-07-12 . Retrieved . 2006-07-14
"GTx Announces Toremifene 80 mg NDA Accepted for Review by FDA" (Press release).
"GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study". 2 Mar 2011.
"Toremifene - AdisInsight". adisinsight.springer.com . Retrieved . 2018-02-08
Taras TL, Wurz GT, Linares GR, DeGregorio MW (2000). "Clinical pharmacokinetics of toremifene". Clin Pharmacokinet. 39 (5): 327–34. doi: 10.2165/00003088-200039050-00002. PMID 11108432.
Harvey HA, Kimura M, Hajba A (2006). "Toremifene: an evaluation of its safety profile". Breast. 15 (2): 142–57. doi: 10.1016/j.breast.2005.09.007. PMID 16289904.
Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA (2006). "Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy". Expert Opin Investig Drugs. 15 (3): 293–305. doi: 10.1517/135437184.108.40.2063. PMID 16503765.
Zhou WB, Ding Q, Chen L, Liu XA, Wang S (2011). "Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials". Breast Cancer Res. Treat. 128 (3): 625–31. doi: 10.1007/s10549-011-1556-5. PMID 21553116.
Gennari L, Merlotti D, Stolakis K, Nuti R (2012). "Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis". Expert Opin Drug Metab Toxicol. 8 (4): 505–13. doi: 10.1517/17425255.2012.665873. PMID 22356442.
Mao C, Yang ZY, He BF, Liu S, Zhou JH, Luo RC, Chen Q, Tang JL (2012). "Toremifene versus tamoxifen for advanced breast cancer". Cochrane Database Syst Rev (7): CD008926. doi: 10.1002/14651858.CD008926.pub2. PMID 22786516.
Vogel CL, Johnston MA, Capers C, Braccia D (2014). "Toremifene for breast cancer: a review of 20 years of data". Clin. Breast Cancer. 14 (1): 1–9. doi: 10.1016/j.clbc.2013.10.014. PMID 24439786. Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL (2014). "Toremifene in the treatment of breast cancer". World J Clin Oncol. 5 (3): 393–405. doi: 10.5306/wjco.v5.i3.393. PMC . 4127610 PMID 25114854.